Physician profile
Lance B Large
NPI 1750362554
$7,310.88
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,096 · 2020: $1,756 · 2021: $1,851 · 2022: $1,884 · 2023: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $624.30 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,264.49 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $783.06 | 2019-2023 | Mounjaro |
| Abbvie INC. | $761.44 | 2021-2023 | |
| Novo Nordisk INC | $532.46 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $456.31 | 2019-2022 | |
| Pfizer INC. | $363.57 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $358.00 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $320.22 | 2019-2023 | Camzyos, Eliquis |
| Amgen INC. | $258.78 | 2019-2021 | |
| Amarin Pharma, INC. | $196.57 | 2019-2021 | |
| Glaxosmithkline, LLC. | $175.25 | 2020-2023 | Trelegy Ellipta, Arexvy, Pediarix |
| Allergan, INC. | $174.33 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $173.56 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $146.42 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $140.74 | 2022-2023 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Large listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.